Uncovering the Rare Bone Disorder: Engelmann's Disease

Introduction

Engelmann's disease is a rare genetic disorder that affects the bones, causing them to become abnormally dense and thick. The disorder was first described by Dr. Georg Engelmann in 1929. Although the prevalence of the disorder is unknown, it is inherited in an autosomal dominant manner and can present with a range of symptoms, from mild to severe. Diagnosis of Engelmann's disease is based on a combination of clinical symptoms, radiological findings, and genetic testing.

What Is Engelmann's Disease?

• Engelmann's disease, also known as Camurati-Engelmann disease (CED) or diaphyseal dysplasia, is a rare genetic disorder affecting bones.

• It is a type of sclerosing bone dysplasia that causes the bones to become abnormally dense and thick.

What Is the Cause of Englemann’s Disease?

• Engelmann's disease is caused by gene mutations that encode transforming growth factor beta 1 (TGF-β1).

• A protein called TGF-1 is essential for controlling bone development and growth.

• TGF-1 gene mutations in individuals with Engelmann's disease result in an overproduction of the protein, which results in aberrant bone development and sclerosis.

• Engelmann's disease is inherited via an autosomal dominant gene mutation in the TGF-1 gene.

• This means that to develop the condition, a person only has to inherit one copy of the faulty gene from either parent.

• The mutation can, however, occasionally happen spontaneously without a history of the condition in the family.

• Not all cases are brought on by TGF-1 gene alterations. In certain instances, the disorder's underlying causes are not fully understood, necessitating more investigation.

What Are the Symptoms of Englemann’s Disease?

Individuals with Camurati-Engelmann disease (CED) experience a range of symptoms, which typically appear during childhood or adolescence.

1. General Symptoms:

• Limb pain.

• Proximal muscle weakness.

• Poor muscular development.

• A wide-based, waddling gait.

• Easy fatigability.

• Headaches.

• Bone pain is also a common symptom, affecting up to 90 percent of individuals with CED. The pain is described as constant, aching, and most intense in the lower limbs. Pain often increases with activity, stress, and cold weather. Many individuals have intermittent episodes of severe pain and incapacitation.

2. Musculoskeletal Symptoms:

• They are also common in CED.

• Decreased muscle mass and weakness are most apparent in the proximal lower limbs, resulting in difficulty when rising from a sitting position.

• Joint contractures occur in 43 percent of individuals.

• Musculoskeletal involvement can lead to varying degrees of lumbar lordosis (extremely curved lower back), kyphosis (exaggerated rounding of the upper back forward), scoliosis (abnormal lateral spine curvature), coxae valga (femur deformity), radial head dislocation, genua valga (knock-knee), hallux valgus (foot deformity), flat feet, and frontal bossing.

3. Neurological Symptoms: Cranial nerve deficits occur in 38 percent of affected individuals, with the most common deficits being hearing loss, vision problems, and facial paralysis. Involvement of the orbit has led to blurred vision, proptosis (eyes bulging out), papilledema (optic disc swelling), epiphora (excessive tear secretion), glaucoma (blindness due to optic nerve damage), and subluxation of the globe.

4. Facial Features: Children with CED usually do not experience changes to their facial characteristics, but older people who are severely affected may get osteosclerosis of the skull, which can cause macrocephaly, frontal bossing, jaw enlargement, proptosis, and cranial nerve impingement causing facial palsy.

How to Diagnose Englemann's Disease?

A combination of clinical symptoms, radiological evidence, and genetic testing is used to diagnose Engelmann's disease. The following examinations and tests may be used to identify Engelmann's disease:

1. Physical Examination: The doctor will examine the patient physically and assess their symptoms and medical background.

2. X-rays: X-rays of the bones can show areas of sclerosis and thickening, which are characteristic of Engelmann's disease.

3. CT Scan or MRI: These imaging tests can provide more detailed images of the bones and soft tissues and may be used to confirm the diagnosis.

4. Bone Biopsy: In some cases, a bone biopsy may be performed to examine the bone tissue for characteristic changes seen in Engelmann's disease.

5. Genetic Testing: Genetic testing can confirm the presence of a mutation in the TGF-β1 gene that causes Engelmann's disease. This can be done through a blood test or a cheek swab.

After the initial diagnosis, management evaluation has to be done to assess the extent of the disease. To give the person the greatest treatment and care plan possible, these examinations are required.

• The first evaluation is a complete skeletal survey, an imaging test that looks at all the bones in the body to assess the extent of the disease.

• The second assessment is for cranial nerve deficits, which involves a neurological examination, audiology evaluation, and ophthalmologic evaluation to check for any nerve-related issues.

• A baseline blood pressure reading should be obtained before Losartan is considered as a possible treatment.

• If acute bone pain is present, a serum ESR (erythrocyte sedimentation rate) and bone scan examination should be done as baseline measures of disease activity.

• A baseline CT (computed tomography) scan of the head and neck should be thought about in patients with radiographic evidence of skull base sclerosis and neurologic complaints to assess the severity of the condition and enable consideration of surgical treatment options.

• Finally, it is recommended to consult with a clinical geneticist and genetic counselor to understand better the genetic basis of the disease and its implications for the individual and their family members.

What Are the Treatment Strategies for Englemann’s Disease?

Currently, Camurati-Engelmann disease (CED) does not follow any specific regimen. Some of the treatment strategies followed to overcome the symptoms include:

• Corticosteroids:

  • Many symptoms, such as discomfort, weakness, aberrant gait patterns, exercise intolerance, flexion contractures, anemia, and hepatosplenomegaly, may be successfully treated with corticosteroid medication.

  • The effectiveness of steroid therapy in avoiding or postponing bone hyperostosis and involvement of the skull is yet unknown.

  • However, the effectiveness of steroid therapy in preventing or delaying bone hyperostosis and skull involvement is still unclear.

  • Some studies have reported reduced sclerosis on radiographic evaluation and decreased radioactivity on bone scintigraphy following steroid therapy, while others have reported no regression of sclerosis on radiographic evaluation.

  • Individuals with severe symptoms may be given a bolus of Prednisolone, followed by rapid tapering to the lowest alternate-day dose that is tolerated.

• Losartan:

  • Losartan is an angiotensin II receptor blocker that has shown promise in improving bone density and reducing pain in individuals with CED.

  • Losartan works by inhibiting transforming growth factor-beta (TGF-beta), which is believed to contribute to bone resorption in CED.

• Surgery:

  • In severe cases of CED, surgery may be necessary to correct skeletal abnormalities or relieve pressure on the nerves. However, surgery is usually reserved for cases where the benefits outweigh the risks.

  • Surgical treatments such as intramedullary reaming may treat persistent bone pain, while craniectomy may relieve increased intracranial pressure and headaches.

Conclusion

In conclusion, Camurati-Engelmann disease is a rare genetic disorder characterized by bone pain, muscle weakness, and skeletal abnormalities. There is no cure for this disease, but treatment options such as corticosteroids can relieve symptoms such as pain and weakness. Surgery may be necessary for persistent bone pain, while craniectomy can alleviate increased intracranial pressure and headaches. Long-term follow-up studies are needed to evaluate the effectiveness of these treatments.